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Background: As the population ages, the relative and absolute number of age-associated diseases such as dementia
will increase. Evaluation of the suitability and intake of medication and pharmacological treatment is an important
aspect of care for people with dementia, especially if they live at home. Regular medication reviews and systematic
cooperation between physicians and pharmacists are not common in routine care. Medication management (MM),
based on such a comprehensive home medication review could help to reduce drug-related problems and costs.
The present article presents a medication management specifically for the application in the ambulatory setting
and describes its implementation as part of a larger trial.
Methods/design: A home medication review (HMR) and MM is implemented as part of the DelpHi study, a
population based prospective, cluster-randomized controlled intervention study to test the efficacy and efficiency
of the implementation of a collaborative care model in primary care.
Participants: people with dementia (PWD) and their caregivers are recruited by the patient’s general practitioner.
Inclusion criteria are a positive screening result for dementia, living at home and regular intake of drugs. PWD are
asked to specify their regular pharmacy which is asked to participate in the study, too.
Intervention: a comprehensive HMR is conducted as computer-assisted personal interview by specifically qualified
Dementia Care Manager (DCM) at the people’s home. It includes detailed information about drugs taken, their storage,
administration, adherence and adverse events. The MM is conducted in cooperation between DCM, pharmacist and
general practitioner and consists of a pharmaceutical evaluation, pharmaceutical recommendations and their
application. Pharmacists are trained and provided with regularly updated information. The MM is designed to
give information and recommendations concerning antidementia drugs, occurrence of drug related problems,
intake of anticholinergic drugs, potentially clinically relevant drug-drug-interactions, adverse drug events and
medication adherence.
Discussion: The DelpHi-approach for medication management employs comprehensive instruments and procedures
in the primary care setting under routine care conditions, and this approach should be useful in improving
pharmacotherapy as part of the comprehensive treatment and care for people with dementia.
Trial registration: The trial is registered at ClinicalTrials.gov, number NCT01401582.
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Western health care systems struggle with the impact of
demographic changes. The aging of the population will
lead to an increase in both the relative and the absolute
number of age-associated diseases, such as dementia.
The term “dementia” refers to a clinical syndrome that
is characterized by the loss of cognitive functions, such
as delayed recall, working memory, orientation, language
or executive functions, and impaired activities of daily
living (ICD-10). The number of people with dementia
(PWD) in Mecklenburg Western Pomerania, a federal
state in the north-east of Germany, is expected to in-
crease by 91.1% between 2005 and 2020 [1]. Actual
dementia-centered care is insufficient. Recently, Thyrian
et al. identified several important working fields to
improve the treatment and primary care for people
with dementia in Germany [2]. For example, there is a
need for adequate diagnosis and treatment. There are
several guidelines, such as the German S3-guidelines
and the British NICE diagnosis guideline for dementia,
which recommend a multistep algorithm for dementia
diagnosis [3]. The algorithm includes the assessment of
a comprehensive clinical history, neurological and psy-
chiatric examination, basic laboratory and structural
neuroimaging An important part of the assessment of
the clinical history is a review of the medical history, and
as such, this is an obligatory element in the algorithm for
dementia diagnosis. However, the aspect of medication
review is limited to negative side effects of anticholinergic
drugs on cognition [4,5]. Anticholinergics compromise
cognition and may lead to a misinterpretation of clinical
assessments. A systematic procedure for medication re-
view and detection of drug-related problems is lacking.
PWD may not be a reliable information source for
medication review because cognitive impairment per se
is associated with a reduced ability to manage pharma-
cotherapy [6].
Drug choice and regular evaluation as a part of medi-
cation management (MM) plays an important role in
care-giving for PWD. In general, the intake of several
drugs is associated with the risk of drug-related problems
(DRP) as well as a high cost for the treatment of adverse
events [7,8]. DRPs comprise several categories, including
drug-drug interactions (DDIs), adherence problems, in-
appropriate drug choice and inappropriate usage by the
patient [9]. The DRP-category “inappropriate medica-
tion” is of specific relevance for the PWD. Anticholinerg
drugs [4] often affect patients’ cognition adversely, in-
crease treatment costs due to increased hospitalizations,
and may cause falls [10-13]. Polypharmacy is a general
co-factor for every DRP category and can be a major
co-factor for increased, non-disease specific cognitive
decline and reduced abilities in the activities of daily
living in elderly patients with dementia. Sedative drugssuch as benzodiazepines are strongly associated with
falls and hip fractures [14]. Even with the appropriate
prescription of every medication, every additionally ad-
ministered drug increases the risk of clinically relevant
drug-drug interactions [15]. DDIs can result in drug-
induced hospitalizations, elevated mortality, and decreased
quality of life. Even DDIs not leading to hospitalizations
often compromise patients’ adherence to their drug
therapy [16]. Recently, Rottenkolber et al. estimated total
costs of 400 Mio. € p.a. for drug-associated hospitaliza-
tions in Germany [7]. Another problem in geriatric
pharmacotherapy is frequent off-label prescribing [17].
This activity leads to the legal dilemma between the
necessity of therapy and the limited therapeutic options,
as many medications are not approved for use in geriatric
patients, resulting in increases in the occurrence of off-
label prescription.
A comprehensive medication review could help to im-
prove the care for PWD. There is evidence for positive
effects of such a review on medication-related and clin-
ical outcomes, such as hospitalizations and mortality, in
elderly people [18-20]. However, neither the German
S3-guidelines nor the NICE-guidelines specify proce-
dures for a medication review or quality management as
part of the diagnosis or treatment of dementia.
The first part of a medication review is a general inter-
view about the patient’s drug intake behavior and a
complete assessment of all drugs taken by the patient,
including the intake modalities (over-the-counter (OTC)
and prescribed) [21]. The patient’s medication list can
be used during this step, however this information is
not always reliable and only 70% of elderly provide a
patient medication list. For those who do have a list,
OTC drugs are often not documented [22]. OTC medi-
cations are important in drug management, as they often
cause clinically relevant drug-drug interactions or fur-
ther DRPs.
Maidment et al. concluded that “medication management
in dementia is a broad concept that should encompass a
complete review of medication, including assessment of
indication, dosage, interactions and continued need” [23].
Medication management may help to improve quality
of care. Earlier publications of the American Health
Association classified medication management as one
of the most important aspects of interventions in disease
management [24]. However, detailed procedures for medi-
cation management in dementia are still not specified.
Medication management is difficult since there are inter-
face problems within the health care system. For example,
in Germany, medication is prescribed by physicians, sold
by pharmacists and purchased by PWD and their care-
givers. Also, a nursing service might coordinate drug ad-
ministration. The German health care system does not
provide a systematic exchange of information between
Fiß et al. BMC Geriatrics 2013, 13:121 Page 3 of 8
http://www.biomedcentral.com/1471-2318/13/121these parties, so that counseling provided to the patient
or caregiver by one party is limited. For example, the
prescription given to the pharmacist contains neither an
indication for drug intake nor a prescribed dosage [25],
the physician does not necessarily know what OTC
drugs are sold or taken. There are no digital interfaces,
such as electronic health records. Collaborative health
care networks, medication management and IT-support
with electronic health records can reduce incomplete
information on the side of the General Practitioner (GP)
and other physician(s) involved in the treatment of an
elderly patient. This counts even more for patients suf-
fering from a dementia syndrome [23,26].
Presently, there is a lack of instruments available for
medication review and for medication management even
though the SOAP (Subjective and Objective problem
Assessment, and Planning of improvement) scheme, which
is based on pharmaceutical care, can help with the medica-
tion management process [22]. However, medication man-
agement is not a well-implemented modality in clinical
and primary dementia care in Germany. Therefore, the
aims of this paper are:
1. To develop procedures and instruments for a home
medication review (HMR) and medication
management process for PWD living at home,
specifically for Germany.
2. To describe the implementation of such an HMR
and medication management process as one module
in a primary care intervention trial designed to
deliver optimum care to PWD living at home.
Methods/design
HMR with a subsequent MM is part of the complex inter-
vention in the DelpHi study (dementia: life and person-
centred support in Mecklenburg Western Pomerania)
[27]. The DelpHi-study is a population based prospect-
ive, cluster-randomized controlled intervention study.
Details of the study design are described in detail else-
where [27]. In the course of this study, the MM described
in this article will be tested for its efficacy by comparing
an intervention group that receives MM versus a control
group that does not receive MM. The complex interven-
tion also comprises caregiver counselling and providing a
subsidiary support system for the care of the PWD, which
is not part of this article.
Participants
The DelpHi-study recruits participants with suspicion
of dementia (DemTect <9 [28]) in GP practices. People
70 years or older, living at home, having sufficient know-
ledge of german and having a regular intake of drugs are
included in the HMR and MM. Participants are asked to
name a caregiver who is then invited to participate inthe trial as well as to designate their regularly visited
pharmacy.
The participating pharmacies are qualified to conduct
the MM in a personal training course and are given com-
prehensive information on the study and further advice on
the MM. The topics covered are:
(a) DelpHi study procedures and standard operating
procedures (SOPs),
(b) basic principles of medication management,
(c) basic principles in the context of drug-related problems,
(d) clinical symptoms of dementia,
(e) special DRPs associated with dementia,
(f ) the pharmacists’ role in the primary health care
network,
(g) hands-on exercises with case-reports
Furthermore, the study pharmacist is available by tele-
phone for clarification of further questions. The training was
accredited by the chamber of pharmacists of Mecklenburg
Western Pomerania.
If the pharmacy chosen by the participant does not
take part in the MM part of DelpHi or the PWD does
not name a pharmacy, the HMR of the respective par-
ticipant will be conducted by the study team pharmacist.
The participants in the control group receive care as usual
(the pharmacist is not actively enrolled in the study).
Data assessment
The baseline assessment for each PWD is conducted as an
interview by specifically qualified Dementia Care Manager
(DCM) [29] in the patient’s household. The aim of the
interview is to capture the real medication care situation
of people with dementia and the PWD is the primary
interview partner. The informal caregiver (if present) can
assist in answering the questions. In case of missing data
other available proxies like participating GPs or a nursing
service are used.
In addition to the HMR described in this article the fol-
lowing data are assessed: sociodemography; health care
utilization; vital status using the STEP-screening [30];
(instrumental) activities of daily living; social integration;
information on dementia (course and causes); quality of
life; depression and cognitive status (SIDAM [31]).
Due to the cognitively demanding nature of the inter-
views, cognitive testing and HMR are conducted apart
from the baseline assessment at a second home visit.
Home medication review
The HMR is a computer-assisted personal interview (CAPI)
delegated to specially qualified nurses [32]. To obtain full
information about medication, a “bathroom cabinet review”
is included. This comprises the look at all the medication
available in the house, prescription drugs and OTC. If drugs
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the nursing service and obtains a copy of the patient’s
medication list. According to a previous review on the
global dimensions of home medication in epidemiology
and health care research [32] our HMR consists of
data on:
 Drugs: brand name; pharmaceutical identifying
number (a special number for the German market
which allows identifying a given preparation and
abstract additional information from pharmaceutical
databanks); active substance, pharmaceutical form, if
possible; daily dosage taken; day and time of drug
intake, timing of drug intake relative to a meal;
intake option (e.g., regular intake, emergency drug,
or no longer needed); prescribing medical
practitioner; medical indication for drug intake; the
actual sales price.
 Drug storage: Where are the drugs stored (to ensure
correct storage conditions, such as temperature and
air humidity)? Additionally, the interviewer checks
whether all of the drugs listed can be found in the
named storage place as recorded.
 Drug administration: Who is available to assist with
drug intake? Is a professional nursing service
involved? Does the patient visit a preferred
pharmacy and GP (to have a contact person if
interfering drugs are identified)? Is drug administration
supported by a relative or other informal caregiver?
Does he or she need additional qualification? Is a
medication list available, is it complete (e.g., over-the
counter drugs; all regularly taken drugs as well as drugs
taken on demand)? Is a drug dispenser used (as an
adherence supporting strategy)?
 Drug adherence: multiple intakes due to
forgetfulness are checked in addition to other
adherence categories (e.g., complete discontinuation,
drug holidays, and single skipped dosages). To
measure this the Morrisky-Score, the MARS scale,
and the CQR are available [33-35] and the German
short form of the MARS scale for adherence
measurement is used [36].
 Adverse drug events according to self-reports.
 Daily fluid intake and the type of drink consumed
(to discover potential interactions: alcohol/
grapefruit juice).
All information is entered in electronic case reporting
forms and stored in a study database [37]. Upon comple-
tion of the HMR the system compiles a standardized
interview report that includes the medication list. The
DCM initiates a comprehensive medication management
by printing a structured documentation which is for-
warded to the patient’s pharmacy and the treating GP.Medication management/intervention
The Medication management is defined as a systematic,
stepwise approach for the detection of DRPs and solution
of DRPs, systematic drug documentation in close collabor-
ation between DCM, pharmacist and GP.
Step 1 Pharmaceutical evaluation
After an initial analysis of the pharmacotherapy, the
pharmacist prepares a list that addresses relevant
drug-related problems. The pharmaceutical evaluation
targets (I) the PWD and his/ her caregiver as well as (II)
the treating GP. For the PWD the pharmacist analyses:
a) drug administration (support in drug
administration - is there a caregiver or a nursing
service involved?),
b) correct drug intake modality (time between
drug administration and meal, time of day,
frequency) and
c) an adherence check (what types of adherence
problems are relevant for the PWD?)
For the GP the pharmacist checks (from a pharmaceutical
point of view!!!):
a) correct drug choice and combination
b) potentially inappropriate medications
c) dosage
d) clinically relevant drug-drug interaction [38,39]
e) plausibility of reported adverse drug events
and adherence
Step 2 Pharmaceutical recommendation
The pharmacist makes suggestions for the adaption of
the pharmacotherapy: identified clinically relevant
drug-drug interactions, appropriate drug choices,
duplicate medications with a special focus on drugs
from similar therapeutic classes, adequate pharmaceutical
formulation, unclear or inconsistent application schemes
etc. In cooperation between GP, DCM and pharmacist
these recommendations are discussed.
Step 3 Application of recommendations
The GP is responsible for pharmacotherapy and
initiates and monitors this. He is provided with all
information about pharmaceutical interventions as well.
Pharmaceutical interventions with the patient can
comprise counseling of the patient and caregiver about
correct drug usage, allocation of a drug dispenser, the
provision of information leaflets about correct drug
intake (short version of the summary of product
characteristics), written adherence support strategies. If
no caregiver is available, the nursing service monitors
drug intake in the patient’s household by the GP.
Documentation of all recommendations and the
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a scheduled point in time, the home medication
iew is repeated to evaluate the success of the
dication management process. An overall workflow
the medication management in the DelpHi study is
ovided in Figure 1. The recommendations for the
ntent of general as well as dementia specific
dication management are provided in Table 1.Quality management
The procedures of the medication management process
are part of a standard operating procedure (SOP), which
is updated regularly in the study center. The SOP is ex-
plained, trained and handed out to the pharmacist and
the GP, and is rechecked and updated regularly by the
study’s physician and pharmacist.
As a part of the study procedure we provide a guideline-
based pharmacotherapy card to the pharmacist that is
compiled by physicians and pharmacists in the study
centre and is updated in the study centre. The card is
written in a practical format and provides a reference
for the pharmacist in the medication management. As a
part of the intervention such card should be of practical
use. The card contains:
a. reminder information about frequent comorbidities
b. information about approved antidementia drugs
and their dosage, bioavailability, renal elimination,
available pharmaceutical formulations,
CYP-metabolism, drug-drug interaction, common
adverse effects, and contraindications
c. general information about therapy for common
psychiatric/ neurologic comorbidities (i.e. agitation,
depression, delusion, sleep disorders)Baseline assess
medication rev
(by pharmacist
- DRP interview 









- adherence monitoring 
- optionally contact with 
nursing service
ure 1 Recommendation for a workflow of the medication managed. general information about DRPs (substances/ intake
modalities that cause them, alternative substances/
intake modalities)
Outcome measures
The MM in Delphi as described in this article is designed
to deliver information about needs in pharmacotherapy
and to trigger activities to reduce these needs. The target
variables are:
a) intake of antidementia drugs (regular intake of
an inhibitor of an acetylcholine esterase or a
NMDA-antagonist)
b) potentially inappropriate medication e.g.
anticholinergic drugs
c) number of potentially clinically relevant drug-drug-
interactions according to the ABDA database [40]
d) adherence
Discussion
The DelpHi approach for medication review employs com-
prehensive instruments and procedures in the primary
care setting, and this approach is able to evaluate the
efficacy of medication management for persons with
dementia. This approach may overcome limitations of
previous research and may be transferable into rou-
tine care.
Studies on the efficacy of medication management
for PWD have focused on nursing homes or other institu-
tionalized settings, or they did not focus on inappropriate
drugs [41-43]. In a recent systematic review of the effects
of medication review the low quality of most studies was
criticized [44]. The most important criticism was the lack
of sufficient randomization and the lack of assessing im-
portant clinical outcomes, such as hospitalisations [44].
The MM described here is designed for the setting ofment incl. 
iew 











ment for patients with dementia.
Table 1 Recommendations for the content of general as well as dementia specific medication management
Content of basic module Content of disease specific module
Medication review Check for anticholinergic drugs
Activities for correct administration/storage Check for falls increasing drugs
Regular (every 6 months) check by the local pharmacist Monitoring of drug usage by a caregiver or nursing service, resp.
activities to improve adherence Check for clinically relevant drug-drug interaction
Check for adverse drug events Adherence-monitoring: pill counting by the pharmacy
Check for potentially inappropriate medication. Supply of adherence supporting tools, as MEMS
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mented in the complex intervention in the DelpHi study
yields a high quality (randomisation, assessment of clin-
ical outcomes and such).
However, there are some challenges in this trial
as well:
1 Standardisation
This study is conducted partially in routine care,
involves different professions and relies on
cooperation and communication. We assume that
adherence to the study protocol and intervention may
be an issue. Monitoring of data quality simultaneously
on different levels is required. However, we use a
computer-assisted data collection and management
system. This system systematically supports the
documentation of the MM. It also supports early
detection of incomplete and implausible data. We
also included partial integration of computerized
decision support which is known to have positive
effects, for example, on the detection of DRP [45].
We also qualify the participating professions extensively;
give continuous support and issue SOPs as well as
the pharmacotherapy card as a reminder tool.
2 Validity of data
Over the course of the progression of dementia,
patients will lose their ability to answer our study
questions. Thus, several monitoring instruments for
drug therapy in the DelpHi study are based on the
caregiver and do not require information solicited in
personal interviews. Including the caregiver, the
patient’s drug data record at the local pharmacy and
the access to the GP’s medical record will help to
improve the validity of our medication and study data.
Our MM will improve pharmacotherapy in PWD
living at home. As one main benefit of a home
medication review, all drugs taken, including OTC-
drugs are recorded. The issue of a comprehensive
medication list helps to identify several drug related
problems [46]. If the patient would only be asked
about the taken drugs or if only drugs from the
medication plan were accounted for in the medication
check, there would be a considerable risk ofunderreporting. We assume that this causes inad-
equate pharmacotherapy that will be not overlooked
in our HMR and MM. Specific targets are the
avoidance of potentially inappropriate medication
as well as anticholinergic drugs. OTC drugs, which
often have anticholinergic properties are often
taken by elderly people and they frequently cause
clinically relevant drug-drug interactions. Hence,
knowing about OTC-drugs we can identify drug-
drug-interactions and try to avoid them. Our MM
will identify problems related to drug administration
that can be encountered by providing additional
assistance with drug administration from, for example,
a professional care giver.
Our MM systematically supports and improves
cooperation between professions that might be
relevant for pharmacotherapy in Germany. The GP
is responsible for pharmacotherapy of the PWD and
is supported by a DCM and a pharmacist. There is
evidence, that a pharmacist may have an important
role in optimizing geriatric pharmacotherapy [47]. In
the DelpHi study we use an electronic health record
documentation that comprises drug documentation.
Based on electronic data management, all relevant
information can be available to all health care
professionals involved in a patient’s care. Written
documents are made available to the partners,
recommendations are written down and
interventions like changes in pharmacotherapy are
documented. This yields comprehensive information
and transparency to all partners.
We expect that the HMR and MM developed for
DelpHi is transferable into routine care once it has
proven its efficacy. It is implemented into a study
close to routine care, incorporates already all
professions that deal with pharmacotherapy of PWD
in routine care and shows a high degree of
standardisation. It is very specific and detailed in its
procedures, complies with the state of the art
guidelines for dementia care and probably requires
just a few adaptations to be efficient in routine care.
The MM can help the PWD by improving his/ her
pharmacotherapy, help the caregiver by reducing
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by providing information/ recommendation not
available in current routine care. In general, we
expect the MM to have positive effects on the
individuals as well as on the health care system.Abbreviations
DCM: Dementia care manager; DDI: Drug-drug interaction; DRP: Drug related
problem; GP: General practitioner; HMR: Home medication review;
MM: Medication management; OTC: Over the counter; PIM: Potentially
inadequate medication; PWD: Person/ patient with dementia; SOP: Standard
operating procedure.
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